The Library
1530 papers on microsampling and monitoring, each with a finding paraphrased to our standard and labelled in one vocabulary. Every entry links to a legitimate copy; nothing is copied from an abstract.
19 papers labelled “biologics”, newest first.
2025
The study found a dried blood spot method for ustekinumab was linear from 3 to 12 mg/L with inter-day accuracy of 90.1 to 106%, enabling reliable capillary blood measurement for remote monitoring; the authors note the single-centre design.
Development, Validation and Application of the Dried Blood Spot Analysis Method for the Determination of Ustekinumab in Patients with Inflammatory Bowel Disease — Mingas et al., Pharmaceuticals
- blood
- dried
- capillary
- dbs
- validation
- tdm
- biologics
2025
The HematoCARD cartridge autonomously collects duplicate 10 microlitre dried blood spot samples from a single finger prick and shows good analytical performance for monitoring adalimumab, with accuracy between 91 and 111 per cent, linearity R squared 0.99 and coefficient of variation at or above 0.94 compared with serum reference and commercial DBS microsampling methods.
HematoCARD: A Volumetric Duplicate Dried Blood Spot Collection Cartridge Validated for Therapeutic Drug Monitoring — Van Hileghem et al., Analytical chemistry (paywalled)
- volumetric
- biologics
- blood
- dbs
- tdm
- haematocrit
- dried
- capillary
- validation
2025
This study validated a method combining quantitative dried blood spots with DNA methylation analysis to monitor B-cell counts remotely, achieving 100% sensitivity and specificity for a specific clinical threshold. This decentralised approach facilitates patient-centric therapeutic drug monitoring for anti-CD20 therapies by overcoming the logistical barriers of regular venous sampling.
Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies — Tallantyre et al., Multiple sclerosis (paywalled)
- biologics
- multimodal
- blood
- rpm
- qdbs
- tdm
- self-collection
- dried
- validation
2025
The method accurately measures therapeutic antibodies in Vams samples, correlating with plasma levels, enabling reliable therapeutic drug monitoring from home-collected samples to optimise cancer treatment dosing
A novel approach for quantifying therapeutic monoclonal antibodies in blood through liquid chromatography-tandem mass spectrometry — Chi et al., Analytica chimica acta (paywalled)
- blood
- vams
- venous-agreement
- tdm
- biologics
- oncology
2025
This feasibility study demonstrated that a surrogate matrix solution enables accurate quantitation of a monoclonal antibody from dried blood samples collected via VAMS or Tasso-M20 devices. The method resolves challenges related to daily calibrator preparation and sample dilution for ligand binding assays used in pharmacokinetic studies.
The Use of Surrogate Matrix for Calibrators in the Analysis of Dried Blood Samples - A Feasibility Study — Lee et al., The AAPS journal (paywalled)
- blood
- dried
- vams
- neoteryx-mitra
- validation
- biologics
2024
Capillary finger prick sampling at home showed close agreement with venous sampling for measuring infliximab, vedolizumab and CRP, with no systematic bias and high patient tolerability and practicality, supporting decentralised monitoring of biologic therapy in IBD.
Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease — Otten et al., Inflammatory bowel diseases
- blood
- liquid
- capillary
- self-collection
- venous-agreement
- acceptability
- tdm
- biologics
2024
Capillary blood collection using liquid and dried microsampling devices yielded pharmacokinetic profiles comparable to venous sampling for two monoclonal antibodies and a small molecule, whereas haematocrit correction was necessary for dried formats and bridging was ineffective for hydroxychloroquine. The findings demonstrate the bioanalytical feasibility and patient acceptability of remote microsampling tools for pharmacokinetic evaluations in decentralised clinical trials.
Evaluation of Patient-Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules — Mandlekar et al., Clinical pharmacology and therapeutics (paywalled)
- blood
- liquid
- dried
- capillary
- neoteryx-mitra
- validation
- venous-agreement
- acceptability
- tdm
- biologics
- dct
- haematocrit
2023
Early at-home VAMS samples allowed Bayesian forecasting of steady-state adalimumab concentrations with modest bias (mean prediction error -2.6%) and acceptable precision (normalised RMSE 24.0%), correctly classifying 75% of predictions within the therapeutic window and identifying 8.3% of patients who developed anti-adalimumab antibodies, supporting decentralised precision dosing during induction.
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study — de Klaver et al., European journal of drug metabolism and pharmacokinetics (paywalled)
- blood
- dried
- vams
- neoteryx-mitra
- self-collection
- tdm
- biologics
2022
An LC-MS/MS method for dried blood spots simultaneously quantifies four therapeutic monoclonal antibodies and estimates haematocrit from haemoglobin peptides with >0.9 correlation to laboratory values, enabling accurate therapeutic drug monitoring from self-collected samples for decentralised care.
Development of an LC-MS/MS method to simultaneously quantify therapeutic mAbs and estimate hematocrit values in dried blood spot samples — Chiu et al., Analytica chimica acta (paywalled)
- blood
- dried
- dbs
- volumetric
- validation
- tdm
- biologics
- haematocrit
2022
In a small substudy of psoriasis patients, lateral flow testing for adalimumab agreed very well with ELISA (r=0.95, R2=0.89) and capillary VAMS from finger prick correlated strongly with serum (r=0.87), while patients found home microsampling acceptable, indicating promise for decentralised TDM of biologics and warranting larger validation.
Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice — Soenen et al., Journal of clinical medicine
- blood
- dried
- capillary
- vams
- self-collection
- venous-agreement
- acceptability
- tdm
- biologics
2021
A review of VAMS and DBS microsampling for TDM of therapeutic monoclonal antibodies, adalimumab, infliximab and others, in inflammatory disease: a convenient, home-friendly alternative to venepuncture that can preserve analytical accuracy, subject to assay-specific validation.
The evolving role of microsampling in therapeutic drug monitoring of monoclonal antibodies in inflammatory diseases — Mingas et al., Molecules
- vams
- biologics
- blood
- dbs
- tdm
- self-collection
- haematocrit
- dried
- validation
2021
In paediatric inflammatory bowel disease patients, infliximab levels measured from dried capillary blood spots strongly correlated with venous serum concentrations, with a mean difference of -0.14 μg/mL and excellent interclass correlation coefficient of 0.998. This demonstrates that finger-prick microsampling is a patient-friendly alternative to venepuncture for therapeutic drug monitoring of biologics in children.
Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients — Zijlstra et al., Journal of pediatric gastroenterology and nutrition (paywalled)
- blood
- dried
- capillary
- neoteryx-mitra
- venous-agreement
- pediatric
- tdm
- biologics
2021
A microfluidic DBS device using hydrophobic burst valves meters 5-15 μL blood accurately across 25-70% haematocrit and, in a therapeutic drug monitoring validation with adalimumab-spiked samples, achieves higher recovery than traditional DBS (86% versus 62%), supporting precise home or low-resource sampling.
Precise sample metering method by coordinated burst action of hydrophobic burst valves applied to dried blood spot collection — Vloemans et al., Lab on a chip (paywalled)
- blood
- dried
- dbs
- validation
- tdm
- biologics
- haematocrit
2021
The study found that daclizumab and trastuzumab showed encouraging recovery from VAMS after short term storage at room temperature and long term storage at -80 degrees Celsius, supporting the use of VAMS for therapeutic drug monitoring of biologics in decentralised settings.
Whole blood stability evaluation of monoclonal antibody therapeutics using volumetric absorptive microsampling — Li et al., Bioanalysis (paywalled)
- blood
- dried
- vams
- neoteryx-mitra
- validation
- tdm
- biologics
2021
VAMS coupled with LC-MS/MS showed good correlation with conventional serum sampling for monoclonal antibody pharmacokinetics in rhesus monkeys, but a subsequent clinical study revealed that EDTA anticoagulant in standard and quality control samples caused anomalous internal standard responses in patient fingerstick samples, compromising accuracy. The authors recommend specific best practices during method development and validation to detect such anticoagulant effects early before deploying VAMS in clinical studies.
Volumetric absorptive microsampling (VAMS®) in therapeutic protein quantification by LC-MS/MS: Investigation of anticoagulant impact on assay performance and recommendations for best practices in method development — Gao et al., Journal of pharmaceutical and biomedical analysis (paywalled)
- blood
- dried
- vams
- neoteryx-mitra
- validation
- venous-agreement
- tdm
- biologics
2021
Two feasibility studies assessed low-volume blood sampling for therapeutic drug monitoring. In patients receiving an anti-A therapeutic, drug levels were measured from finger-prick whole blood collected with Neoteryx Mitra and from capillary plasma collected with TASSO OnDemand, and compared with venipuncture samples. The work outlines practical considerations for adopting these patient-centric microsampling methods in decentralised trials and clinical care.
Assessment of low volume sampling technologies: utility in nonclinical and clinical studies — Williams et al., Bioanalysis (paywalled)
- blood
- capillary
- vams
- neoteryx-mitra
- validation
- venous-agreement
- tdm
- biologics
2020
In 33 patients, dried blood spots showed high correlation with venipuncture for adalimumab, Pearson ≥0.96, whereas home sampling showed moderate correlation with predicted concentrations, Pearson 0.51.
Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples — Berends et al., Therapeutic Drug Monitoring (paywalled)
- venous-agreement
- biologics
- blood
- dbs
- tdm
- self-collection
- dried
- capillary
2019
A clinical validation showing dried blood samples can support infliximab concentration monitoring in inflammatory bowel disease.
Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation — Berends et al., British Journal of Clinical Pharmacology
- venous-agreement
- biologics
- blood
- dbs
- tdm
- self-collection
- dried
- validation
2017
Finger-prick dried blood spots supported monitoring of both adalimumab and anti-adalimumab antibodies in inflammatory rheumatic disease: biologic TDM without a venous draw.
Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory rheumatic diseases — Kneepkens et al., British Journal of Clinical Pharmacology (paywalled)
- venous-agreement
- biologics
- blood
- dbs
- tdm
- self-collection
- dried
- validation
Read from the corpus on .